2m 2m 2m 2m 2m 2m 2m
- $153.6BMarket Cap
- 7.39%1-Year Change
- Diagnostics & ResearchIndustry
Danaher (DHR)
Key Performance
More- Earnings Score: 46
- Momentum Score: 36
- True Yield: N/A
- Financial Health Score: 32
Latest Research & News
The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR.
10/06/2026, 4:54 AM • GlobeNewswire
Europe's Point of Care (POC) Diagnostics Market is projected to grow from US$8.9 billion in 2024 to US$21.4 billion by 2031, with a 13.4% CAGR driven by rapid testing innovation, molecular diagnostics advancement, and increasing prevalence of infectious and chronic diseases. Germany leads the regional market, supported by strong healthcare infrastructure and public health initiatives. Key players include Siemens AG, Abbott Laboratories, Roche, bioMerieux, Bio-Rad, QIAGEN, Nova Biomedical, Polymer Technology Systems, and Danaher Corp.
10/05/2026, 10:00 AM • GlobeNewswire
The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.
10/05/2026, 6:44 AM • GlobeNewswire
The global cell and gene therapy biomanufacturing market is projected to grow from $5.0 billion in 2026 to $8.7 billion by 2031, driven by an 11.7% CAGR. Growth is fueled by increasing regulatory approvals, rising demand for scalable manufacturing infrastructure, and investments in automation and modular systems. However, high production costs, regulatory complexity, and workforce shortages remain significant challenges.
10/05/2026, 5:58 AM • GlobeNewswire
The global magnetic beads market is projected to grow from USD 3.90 billion in 2026 to USD 6.18 billion by 2032, driven by automation, molecular diagnostics, genomics, and bioprocessing applications. Key growth drivers include adoption of automated magnetic separation platforms, advanced surface chemistries, AI-enabled workflow optimization, and expanding diagnostics capacity across regions. Strategic priorities for industry leaders include developing application-specific chemistries, strengthening supply-chain resilience, and leveraging AI analytics.
10/05/2026, 4:58 AM • GlobeNewswire
The global continuous bioprocessing technologies market is projected to grow from USD 4.8 billion in 2026 to USD 8.5 billion by 2031, driven by rising biologics demand, regulatory support, and the biopharmaceutical industry's shift from batch to continuous production. Key growth drivers include cost efficiency, improved quality, and faster time to market, though high capital investment and technical complexity remain challenges.
10/01/2026, 11:00 AM • GlobeNewswire
The global Therapeutic Drug Monitoring (TDM) consumables market is projected to grow from USD 364.27 million in 2026 to USD 586.85 million by 2032, driven by an 8.22% CAGR. Growth is fueled by AI-enabled automation, integrated lab workflows, standardized collection devices, and improved specimen integrity. Key drivers include workflow integration, digital connectivity, and responsible AI governance across diverse regional markets with distinct operational priorities.
09/28/2026, 4:58 AM • GlobeNewswire
The global Automated Microscopy Market is projected to reach USD 16.63 billion by 2035, growing at 7.35% CAGR, driven by AI-enabled image analysis, whole-slide digital pathology, and expanding applications in life sciences and semiconductor inspection. The U.S. market is expected to reach USD 5.19 billion by 2035 at 7.1% CAGR, while Asia Pacific is the fastest-growing region at 9.8% CAGR. Software is the fastest-growing segment, with electron microscopy emerging as the fastest-growing type.
09/22/2026, 8:30 PM • GlobeNewswire
The global metabolomics market is projected to grow from USD 2.81 billion in 2025 to USD 9.01 billion by 2035, expanding at a CAGR of 12.36%. Growth is driven by precision medicine, biomarker discovery, and multiomics adoption, with oncology accounting for over 44% of the market. However, Q1 2026 faced challenges from geopolitical tensions, supply chain disruptions, and elevated logistics costs affecting laboratory budgets and procurement timelines.
09/22/2026, 8:00 AM • GlobeNewswire
The global magnetic bead purification kits market reached $4.08 billion in 2025 with an 11.6% CAGR and is projected to grow to $6.73 billion by 2030 (10.5% CAGR) and $10.42 billion by 2035 (9.1% CAGR). Growth is driven by expanding genomics research, molecular diagnostics, and high-throughput screening. Semi-automated kits dominate at 51.8% market share, while Asia-Pacific is the fastest-growing region at 12% CAGR. Key challenges include skilled labor shortages and automation infrastructure dependencies.
09/21/2026, 4:56 AM • GlobeNewswire
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.
09/04/2026, 5:48 AM • GlobeNewswire
Lateral Flow Assay Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035
The global lateral flow assay market is projected to grow from USD 10.84 billion in 2025 to USD 17.66 billion by 2035, with a 5.0% CAGR. Growth is driven by increased adoption of point-of-care testing, technological innovations including CRISPR-based assays, and the shift toward decentralized diagnostic models. Major players include Abbott, Roche, Siemens Healthineers, and Thermo Fisher Scientific, with infectious disease testing accounting for 72.2% of market share.
08/31/2026, 5:04 AM • GlobeNewswire
The global laboratory informatics market is projected to grow at a CAGR of 5.06% from 2025 to 2035, driven by increased data processing demands, regulatory compliance requirements, and adoption of cloud-native solutions and AI-driven analytics. North America leads with 42.55% market share, while Asia-Pacific is the fastest-growing region. Services and LIMS products dominate, with cloud delivery and electronic lab notebooks showing the strongest growth rates.
08/27/2026, 11:00 AM • GlobeNewswire
Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
Danaher stock declined 12.1% this week despite beating Q2 earnings estimates and raising full-year EPS guidance. The sell-off was triggered by the revelation that most of the guidance increase ($0.07-$0.08) comes from the Masimo acquisition rather than organic growth, and by reduced biotechnology sales growth expectations due to timing shifts in consumables shipments. The article suggests the market overreacted, as shipment delays in biotech are typically temporary.
07/24/2026, 10:13 AM • The Motley Fool
The global biochemistry analyzer market is projected to reach $8.18 billion by 2035, driven by increasing diagnostic testing demand, adoption of fully automated systems, artificial intelligence integration, and rising preventive screening programs. The market encompasses various product types, modalities, and applications across hospitals, diagnostic centers, and research institutions globally.
07/15/2026, 5:24 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/07/2026
Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Key Executives
- Rainer Blair
- Matthew R. McGrew
- Matthew E. Gugino
- Julie Sawyer Montgomery
- Christopher Paul Riley
Current Ownership Distribution
- Institutions10.7B (74.36%)
- Mutual Funds3.7B (25.59%)
- Insiders7.4M (0.05%)
- Other0 (0.00%)